Obtenção e avaliação do potencial imunoadjuvante de nanopartículas de quitosana na produção de antissoro contra a peçonha da serpente Crotalus durissus cascavella
Snakebite envenoming is a tropical disease neglected in many regions of the world world. In Brazil, the Crotalus durissus cascavella (CDC) snake belongs to a genus with venom of highest lethality. A search for new immunoadjuvants aimed to expand the therapeutic alternatives to improve vaccines an...
Na minha lista:
| Autor principal: | |
|---|---|
| Outros Autores: | |
| Formato: | Dissertação |
| Idioma: | pt_BR |
| Publicado em: |
Brasil
|
| Assuntos: | |
| Endereço do item: | https://repositorio.ufrn.br/jspui/handle/123456789/26691 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
| Resumo: | Snakebite envenoming is a tropical disease neglected in many regions of the world world.
In Brazil, the Crotalus durissus cascavella (CDC) snake belongs to a genus with venom
of highest lethality. A search for new immunoadjuvants aimed to expand the therapeutic
alternatives to improve vaccines and antivenom. Thus, this approach proposed to produce
small and narrow-sized cationic CDC venom-loaded chitosan nanoparticles (CHNP), by
the two association method: adsorption and incorporation, able to induce antibody
response against the CDC venom. The ionic gelation method induced the formation of
stable and slightly smooth spherical nanoparticles (< 160 nm) with protein loading
efficiency superior to 90%. The interactions between venom proteins and CHNP assessed
using Fourier transform infrared spectroscopy corroborated with the in vitro release
behavior of proteins from nanoparticles. Finally, the immunization animal model using
BALB/c mice demonstrated the higher effectiveness of CDC venom-loaded CHNP,
mainly by the adsorption method, compared to aluminum hydroxide, from the dilution 1:
6400 to 1: 25600 for the concentration of 0.5% and up to the dilution of 1: 3200 to 1.0%
of the venom. Thus, CHNPs loaded with CDC venom exhibited a promising
biotechnological approach to immunoadjuvant future. |
|---|